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Introduction
There is an unmet need for new diagnostic biomarkers that 
can improve the detection of adenomas and colorectal cancer 
(CRC) in a cost-effective manner for population screening pro-
grams. Genes whose expression changes markedly in association 
with colorectal neoplasia are therefore potential biomarkers, 
especially if the change can be detected in a non-invasive patient 
sample such as blood or stool. Changes in gene expression may be 
accompanied by changes in DNA methylation at the gene locus 
and abnormal methylation of genomic regions, such as promot-
ers, CpG islands and CpG island “shores,” is a common feature of 
many cancer types, including CRC,1,2 providing the opportunity 
for development of assays for cancer detection.3,4 In CRC, the 
methylation levels of specific genes may serve as cancer biomark-
ers; for example, methylation-specific assays have been developed 
to detect cancer-derived SEPT9 and VIM1 DNA in blood and 
fecal samples, respectively.5,6 The advent of methods for genome-
wide analysis of DNA methylation has provided an opportunity 
to survey the genome comprehensively for cancer-associated 
alterations that occur with high frequency. This has stimulated 
a search for new diagnostic biomarkers, as well as for individual 
genes or multi-gene panels whose DNA methylation status might 
allow tumor classification, prognosis, and the prediction of likely 
response to different treatment options. Moreover, since the iden-
tification and removal of colorectal adenomas prevents their pro-
gression to CRC,7,8 the early detection of colorectal neoplasia in 
population screening could actually lower the incidence of CRC.9
In preliminary analysis of data collected using a new genome-
wide method to inspect DNA methylation levels, we identified 
cancer-specific hypermethylation at a TaqI site within a previ-
ously uncharacterized human RefSeq gene, LOC100526820, on 
the minus strand at chr6:163 834 097–163 834 982 (hg19 coordi-
nates). As seen in Figure S1, this gene is located adjacent to the 
QKI gene, which is on the plus strand and which was included 
in a set of genes that we had previously identified as being down-
regulated in CRC and adenomas (Supplementary Table 1 of ref. 
10). QKI was also recently proposed to be a tumor suppressor 
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the CAHM gene (Colorectal Adenocarcinoma HyperMethylated), previously Loc100526820, is located on chromosome 
6, hg19 chr6:163 834 097–163 834 982. it lacks introns, encodes a long non-coding rNA (lncrNA) and is located adjacent 
to the gene QKI, which encodes an rNA binding protein. Deep bisulphite sequencing of ten colorectal cancer (crc) 
and matched normal tissues demonstrated frequent hypermethylation within the CAHM gene in cancer. A quantitative 
methylation-specific pcr (qMsp) was used to characterize additional tissue samples. With a threshold of 5% methylation, 
the CAHM assay was positive in 2/26 normal colorectal tissues (8%), 17/21 adenomas (81%), and 56/79 crc samples (71%). 
A reverse transcriptase-qpcr assay showed that cAhM rNA levels correlated negatively with CAHM % methylation, and 
therefore CAHM gene expression is typically decreased in crc. the CAHM qMsp assay was applied to DNA isolated from 
plasma specimens from 220 colonoscopy-examined patients. Using a threshold of 3 pg methylated genomic DNA per mL 
plasma, methylated CAHM sequences were detected in the plasma DNA of 40/73 (55%) of crc patients compared with 
3/73 (4%) from subjects with adenomas and 5/74 (7%) from subjects without neoplasia. Both the frequency of detection 
and the amount of methylated CAHM DNA released into plasma increased with increasing cancer stage. Methylated 
CAHM DNA shows promise as a plasma biomarker for use in screening for crc.
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1072 epigenetics Volume 9 issue 8
gene whose expression is decreased in CRC, a change accom-
plished at least partially by DNA methylation.11 Our interest in 
this uncharacterized gene was further heightened when it was 
classified as a long non-coding RNA, particularly in the context 
that the neighboring QKI gene encodes an RNA binding protein. 
lncRNAs are increasingly implicated in cancer12 and are poten-
tially useful for cancer diagnosis.13 Examples of lncRNAs that are 
upregulated in colorectal neoplasia have recently come to light, 
e.g., CRNDE14 and HOTAIR.15
LOC100526820 has now been given the gene symbol 
CAHM, for Colon Adenocarcinoma HyperMethylated. On bioin-
formatics grounds (including the lack of a viable open reading 
frame) the gene is considered not to encode a protein, is classi-
fied as “ncRNA” in the NCBI Gene database (http://www.ncbi.
nlm.nih.gov/gene/?term=CAHM%20gene) and is assigned a 
lncRNA identifier (LINC00468). The RefSeq gene locus com-
prises a single exon and CAHM transcripts are unspliced; this, 
along with ENCODE data describing the histone marks and 
Figure 1. the CAHM gene locus (Loc100526820). (A) the region on chromosome 6 encompassing the CAHM gene and the first exon of the adjacent QKI 
gene. Arrows show the directions of transcription. Double-headed arrows show the positions of two regions selected for bisulphite sequencing: region 
A spanned chr6:163,834,295–163,834,500 (left double-headed arrow, black), region B spanned chr6:163 834 621–163 834 906 (center double-headed 
arrow, gray). the nucleotide sequences of regions A and B are those on the plus strand of the chromosome. primer locations are highlighted in gray, and 
interrogated cpG sites (bold, underlined) are numbered with the last three digits of their chromosomal nucleotide position. the differentially methyl-
ated cytosine in the taqi site from the initial Bisulphite-tag survey is marked by an asterisk (*). the segment used later as template for the methylation-
specific qpcr assay is highlighted in green, while a dotted line has been placed above that used later in rt-qpcr for cAhM expression. the graphs (right) 
show the fraction of methylated cytosines at (B) the 15 individual cpG sites in region A and (C) the readable sites in region B (identified by the last three 
digits of their chromosomal nucleotide position) for each of the 10 matched crc (red) and normal (blue) samples. Also shown is the result for the WBc 
DNA (black) and a 50:50 control mix (green).
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www.landesbioscience.com epigenetics 1073
transcription factor binding at the locus are shown in Figure 
S1.
In this paper, we first describe an examination of the meth-
ylation level across the LOC100526820/CAHM gene locus in 
normal and neoplastic colon tissue specimens. Having devel-
oped a methylation-specific PCR (qMSP), we then demonstrate 
that CAHM is methylated at the sites of the qMSP primers in 
a high proportion of colorectal adenomas and cancers, but not 
in normal colorectal tissue. We observe that the hypermethyl-
ation of CAHM in colorectal adenomas and CRC is accompanied 
by a decrease in its transcription; this downregulation contrasts 
with elevated transcription of lncRNAs such as CRNDE and 
HOTAIR in CRC. We further demonstrate that methylated 
CAHM sequences can be detected in the plasma of patients with 
CRC, and thus may potentially contribute to assays for the detec-
tion of CRC using non-invasive samples.
Results
Identification of CAHM, a novel gene hypermethylated in 
colorectal adenocarcinoma
“Bisulphite-tagging,” a method that interrogates the meth-
ylation status of the CpG site within TaqI (5′-T′CGA) and 
MspI (5′-C′CGG) restriction sites in the genome, was applied 
to DNA isolated from three CRC cell lines, SW480, HCT116, 
and LIM1215, as well as to DNA from eight pairs of CRC and 
matched normal tissue samples10,16. Among the CpG sites methyl-
ated in CRC tissue and cell lines, but not in normal tissue, was a 
cytosine lying within the previously uncharacterised RefSeq gene 
LOC100526820. The cytosine, part of a TaqI restriction site, had 
the coordinate chr6:163 834 406 (Fig. 1A). LOC100526820 is 
located adjacent to the QKI gene, but transcribed in the opposite 
direction (Fig. 1A).
Figure 2. Methylation-specific qpcr assay for CAHM. (A) top strand: fully methylated DNA, with cpG sites shown in blue capitals; m = methyl group. 
Bottom strand: bisulphite-converted equivalent, with thymidines derived from unmethylated cytosine nucleotides shown in red lower-case. Arrows: 
positions and sequences of the methylation-specific oligonucleotide primer pair (Table S2, pcr assay iD 3). (B) standard curve (filled circles) for the 
CAHM methylation-specific qpcr assay, shown as a plot of mean ct values ± seM (n = 36 for each point) for a 4-fold serial dilution of positive control 
bisulphite-treated methylated DNA in negative control bisulphite-treated unmethylated DNA. open circle: 31 of the 36 WBc DNA samples gave no sig-
nal in the CAHM qpcr assays and an arbitrary value of “60” was assigned to these negative samples. thus, the data point is the mean value of 5 measured 
ct values and 31 negative “60” values.
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1074 epigenetics Volume 9 issue 8
Bisulphite conversion-specific deep sequencing was used 
to determine the level of methylation in two chromosomal 
regions: chr6:163 834 295–163 834 500 (“Region A”) and 
chr6:163 834 621–163 834 906 (“Region B”), the former of which 
overlaps the originally identified TaqI site (Fig. 1A). Sequencing 
was done on bisulphite-converted DNA extracted from ten previ-
ously untested CRC and matched normal tissue specimens.
For Region A, between 100 and 600 reads of individual bisul-
phite-treated strands were obtained for each sample. The sequenc-
ing revealed that 7 of the 10 CRC samples showed high levels of 
methylation (60–90%) at the majority of CpG sites (Fig. 1B); 
of the remaining three samples, two showed intermediate lev-
els (30–50%) and one showed minimal (<10%) methylation. 
In contrast, 8 of the 10 normal DNA samples showed methyla-
tion of less than 10% at CpG sites across Region A (Fig. 1B); of 
the remaining two, one displayed low levels (10–20%), and the 
other, intermediate levels (~40%). The CRC tissue sample from 
the patient with ~40% methylation in matching normal tissue 
was one of those showing very high methylation (80–90%), indi-
cating that a further increase had still occurred in neoplasia. The 
sequencing also revealed that commercially-sourced WBC DNA 
(Roche) contained less than 3% methylation at all CpG sites in 
Region A (Fig. 1B), and could therefore be used as an unmethyl-
ated DNA control.
The sequencing data obtained from Region B was of poor 
quality, probably due to its high GC content (73%) and data 
points are only shown where there were >10 reads at a CpG site. 
Despite this, high methylation of the ten CpGs in the final 70 bp 
of the amplicon (i.e., closest to the presumed TSS of CAHM) was 
clearly seen in CRC but not in normal samples (Fig. 1C), indi-
cating that CRC-associated methylation is not unique to Region 
A but most likely extends across the whole CAHM gene locus. 
Segments upstream of Region B were also investigated but failed 
to yield any sequence data, probably because of their very high 
GC content (e.g., the 200 nt surrounding the presumed CAHM 
TSS at the 5′ terminus of the locus is 81% GC, while the cor-
responding segment at the QKI TSS is 83% GC).
Based on the relationship between high CAHM methyla-
tion and CRC revealed by the bisulphite-tag and bisulphite deep 
sequencing data, the HUGO Gene Nomenclature Committee 
(HGNC) approved renaming of LOC105526820 as Colon 
Adenocarcinoma HyperMethylated (non-protein coding), gene 
symbol CAHM.
CAHM hypermethylation in neoplastic colorectal tissue
A quantitative methylation-specific qPCR assay (qMSP) for 
CAHM was developed whose primers span six CpG sites in the 
CAHM locus (Fig. 2A). After optimization of the assay, a plot 
of Ct values vs. amount of methylated DNA demonstrated good 
linearity (R2 = 0.9584) down to 20 pg and sensitivity down to 5 
pg of methylated DNA (equivalent of 1–2 genomic copies) in a 
total of 5 ng DNA (Fig. 2B). The assay only rarely gave a signal 
for WBC DNA, which is essentially unmethylated (Fig. 2B).
The extent to which CAHM was methylated at the qPCR tar-
get sites was measured in bisulphite-converted DNA extracted 
from 126 colorectal tissue specimens comprising 26 normal, 21 
adenoma and 79 CRC, the cancer samples spanning Stages I to 
IV. A qMSP result indicating that 5% or more of the DNA in 
the sample was methylated at the sites targeted by the PCR prim-
ers was considered to be positive, and this was taken to indicate 
that CAHM was substantially methylated (i.e., hypermethyl-
ated) in that sample. The proportion of methylated CAHM (% 
methylation) was substantially higher in neoplastic samples (i.e., 
Table 1. prevalence of methylated CAHM in DNA from tissue and plasma samples
Tissuea Plasmaa
CAHM ≥ 5% methylation meCAHMeqgDNA ≥ 3 pg/ml
Tissue Disease stage Total (n) Matched (n) Positive (n) Positive % Total (n) Positive (n) Positive %
colorectal Normal 26 6 2 8 74 5 7
Adenoma 21 1 17 81 73 3 4
crc stage i 20 4 10 50 12 5 42
crc stage ii 21 1 15 71 21 11 52
crc stage iii 30 0 25 83 23 12 52
crc stage iV 8 0 6 75 12 9 75
crc unknown - - - - 5 3 60
Lung Normal 10 10 0 0 - - -
cancer 10 10 0 0 - - -
prostate Normal 5 5 0 0 - - -
cancer 5 5 0 0 - - -
Breast Normal 10 10 0 0 - - -
cancer 10 10 2 20 - - -
colon Normal 10 10 1 10 - - -
cancer 10 10 8 80 - - -
atissue and plasma samples are from different cohorts of patients; - indicates not applicable or no data available.
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www.landesbioscience.com epigenetics 1075
adenoma and CRC) than in normal colorectal tissue. With the 
threshold of 5% methylation, the CAHM assay was positive in 
2/26 normals (8%), 17/21 adenomas (81%), and 56/79 cancers 
(71%) (Table 1). The proportion of methylated CAHM was sta-
tistically significantly higher in adenomas and CRC Stages II-IV 
than in normal colorectal specimens (P < 0.0002), with median 
CAHM methylation levels of 17–40% in neoplastic colorectal 
specimens (Fig. 3). Hypermethylation of CAHM was observed 
in a high fraction (17/21) of adenoma samples, indicating that 
this is a common early event in CRC development.
For DNA from 11 adenomas and 68 cancer samples, we also 
measured the proportion of the SEPT9 gene that was methyl-
ated (Table S3). While SEPT9 was more frequently methylated 
in CRC, CAHM was methylated in 8 of 11 adenomas compared 
with 7 of 11 for SEPT9 (5% threshold for positives), and for 3 
of the 11 adenomas the proportion of CAHM that was methyl-
ated was at least 2-fold higher than the corresponding value for 
SEPT9. This was also the case for one Stage I and one Stage II 
cancer. The substantially higher level of methylated CAHM in 
some neoplastic samples, particularly adenomas and early stage 
cancers, suggests that its diagnostic use in combination with 
SEPT9 may add to the sensitivity of detection of colorectal neo-
plasia-derived DNA.
CAHM methylation correlates with of loss expression of 
CAHM RNA in colorectal tissue and CRC cell lines
To investigate transcription from the CAHM locus, we used 
a primer pair targeting a region (dotted line in Fig. 1A) in the 
less GC-rich 3′- half of the predicted CAHM RNA transcripts. 
RT-qPCR confirmed the presence of CAHM transcripts in 
RNA extracted from normal colorectal tissue (Fig. 4A).
In all but one tissue pair (n = 17), we observed a decrease 
in CAHM transcription in CRC relative to matched normal 
colorectal tissue (Fig. 4A); the exception had similar levels in 
both samples. In Figure 4A, the median relative expression 
values for CAHM changed from 0.0586 (normal) to 0.0073 
(CRC), representing an 8.0-fold and significant difference (P 
< 0.0001 in paired t test; n = 34). The expression of CAHM 
RNA in colorectal tissue was seen to correlate negatively with 
the extent of CAHM gene methylation, with a highly nonlinear 
dose-response relationship (Fig. 4B). In CRC cell lines, CAHM 
expression again correlated negatively with CAHM methylation 
in a nonlinear fashion (Fig. 4C). Specifically, CaCo2—the 
only cell line with no CAHM methylation—showed significant 
Figure 3. prevalence of methylated CAHM DNA in normal and neoplastic colorectal tissue. the CAHM qMsp assay (Table S2, pcr assay iD 4) was used to 
measure the proportion of methylated CAHM in 5 ng bisulphite-converted DNA from 126 colorectal tissue specimens including normal (open circles, n 
= 26), adenoma (dotted open circles, n = 21) and 79 crc (light gray: stage i, n = 20; medium gray: stage ii, n = 21; dark gray: stage iii, n = 30; black: stage 
iV, n = 8), horizontal bars = median. Dotted line represents 5% methylation, and the count of specimens with ≥5% CAHM methylation is summarized 
in Table 1. the mean levels of methylation for each of the 6 tissue specimen groups are given at the bottom of the figure. ***P value < 0.0002; ns, non-
significant, relative to normal.
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1076 epigenetics Volume 9 issue 8
CAHM expression, comparable to the highest levels seen in 
normal colorectal tissue (Fig. 4A), whereas all of the other cell 
lines (for which ≥3% of the qMSP target regions were meth-
ylated) showed little or no expression (Fig. 4C). The highest 
observed levels of CAHM RNA expression, namely those in 
normal colorectal tissue and in CaCo2 cells, were still less than 
30% of HPRT or <0.3% of β-actin mRNA expression (Fig. 4A 
and C).
CAHM hypermethylation in other cancer types
To evaluate whether hypermethylated CAHM was specific 
for colorectal neoplasia, the methylation status of CAHM was 
measured in matched cancer/normal tissue specimens from lung 
(10 pairs), prostate (5 pairs), and breast (10 pairs), as well as 10 
pairs of previously untested CRC/normal specimens. With the 
same threshold as used above (5% of qMSP targets methylated), 
CAHM was validated as hypermethylated in 8/10 (80%) and 
1/10 (10%) matched CRC and normal specimens, respectively 
(Table 1). CAHM was found to be hypermethylated in only 2 
other cancer specimens, namely breast cancer (2/10, 20%), 
Figure 4. expression of cAhM rNA in colorectal tissue. (A) histogram showing cAhM transcript expression in colorectal tissue samples (normal, blue; 
crc, red), as measured by rt-qpcr (relative to hprt1 expression). for comparison, the level observed in the highest-expressing crc cell line (caco2, 
orange) is also shown. (B) cAhM expression in colorectal tissue samples (normal, blue; crc, red) plotted against the corresponding proportion of meth-
ylated CAHM, as measured by the qMsp assay (relative to hprt1 expression). the inset graph shows the data replotted on a log-log scale. (C) cAhM 
expression in crc cell lines plotted against CAHM methylation, as measured by qMsp (relative to β-actin expression). fill colors are caco2, orange (as in 
panel A); Ls174t, green; ht29, cyan; LiM1215, orange; sW480, magenta; sW620, blue; hct116, gray.
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www.landesbioscience.com epigenetics 1077
whereas it was not methylated in lung or prostate cancer samples. 
Only 1 of the 35 normal samples in the panel—a colorectal tissue 
specimen—tested positive (3%).
Increased levels of hypermethylated CAHM in blood from 
CRC patients compared with normals
The high proportion of methylated CAHM DNA seen in most 
CRC specimens and the low proportion of methylated CAHM 
seen in most healthy tissue specimens and in WBC DNA led us 
to investigate whether the level of methylated CAHM DNA in 
non-invasive samples (such as blood fractions) could be used to 
distinguish CRC patients from healthy individuals. The poten-
tial for background levels of methylated DNA (e.g., from white 
blood cells) to cause false positives in blood from healthy sub-
jects is a major concern in such assays17. We therefore explored 
the detection of methylated CAHM sequences in bisulphite-
converted DNA extracted from plasma of 220 patients who 
were classified by colonoscopy to include 74 normal patients, 73 
with adenoma and 73 with CRC. Each of the triplicate assays 
contained DNA isolated from the equivalent of 0.55 mL of 
plasma. The level of methylated CAHM sequences measured in 
each plasma sample is shown in Figure 5. Using a threshold of 
3pg meCAHMeqgDNA per mL plasma, we obtained a positive 
result with 5/74 (7%) normal patients, 3/73 (4%) patients with 
colorectal adenomas, and 40/73 (55%) CRC patients (Table 1). 
Sixty-nine of 74 plasma specimens collected from healthy con-
trols yielded no detectable methylated CAHM (Table 1), cor-
responding to a specificity of 93%.
Model for estimation of class probabilities—CAHM meth-
ylation levels in blood reflect disease severity
A statistically significant increase in the estimated mass of 
methylated CAHM DNA in plasma drawn from patients with 
Stage II, III to IV CRC was observed, relative to normal plasma 
(Fig. 5). We sought to model the relationship between methyl-
ated CAHM levels in plasma and cancer stage, and to estimate 
the likelihood of a particular cancer stage for a given meCAH-
MeqgDNA value. The corresponding distribution profiles were 
calculated (Fig. 6A) using meCAHMeqgDNA values for plasma 
specimens from patients with known phenotypes (as shown in 
Fig. 5, but omitting the “no signal” results), including the phe-
notype classes: normal, adenoma, early stage CRC (= Stage I + 
Stage II) and late stage CRC (= Stage III + Stage IV). The mod-
eled density plots, assuming the observed methylation levels were 
drawn from a normal distribution (Fig. 6B), were used to estimate 
the cumulative probability that a plasma sample of a known clas-
sification would yield an observed meCAHMeqgDNA amount 
such that its natural log exceeds 1.0, 2.0, and 5.0 (Fig. 6C and 
Figure 5. Level of hypermethylated cAhM DNA in blood plasma. the cAhM qMsp assay (Table S2, pcr assay iD 4) was used to measure of the level 
of CAHM methylation in bisulphite-converted DNA extracted from the equivalent of 0.55 mL plasma (triplicates) from 220 plasma samples obtained 
from colonoscopy-confirmed patients, of whom there were 74 normal (open circles), 73 adenoma (dotted circles) and 73 crc (light gray: stage i, n = 12; 
medium gray: stage ii, n = 21; dark gray: stage iii, n = 23; dark: stage iV; crossed circles: unknown stage, n = 5). Data points are mean pg mecAhMeqgDNA 
per mL plasma. Dotted line: 3 pg/mL threshold. the number of specimens with >3 pg/mL mecAhMeqgDNA is summarized in Table 1. the mean levels 
of methylation for each of the seven phenotypic groups of patients are given at the bottom of the figure. ***P value < 0.0002; ns, non-significant, as 
compared with normal.
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1078 epigenetics Volume 9 issue 8
dotted lines and top arrows in Fig. 6B). We determined that only 
3% of premalignant (= normal + adenoma) plasma specimens are 
found to contain 148 pg or more of meCAHMeqgDNA, whereas 
66% of late stage CRC show 148 pg or more. Thus the likelihood 
of a plasma specimen with ≥148 pg meCAHMeqgDNA to be 
a late stage CRC is 23:1 (late stage: premalignant). Further, a 
plasma specimen with ≥22 ng of meCAHMeqgDNA is approxi-
mately 1600 times more likely to be drawn from a patient with 
late stage CRC than from a healthy patient or one with prema-
lignant neoplasia.
Discussion
The gene name Colon Adenocarcinoma HyperMethylated 
(non-protein coding), gene symbol CAHM, has been assigned 
to LOC100526820 (hg19 chr6:163 834 097–163 834 982) based 
on the results described above, which demonstrate increased 
methylation in colorectal neoplasia relative to normal colon 
mucosa. The CAHM gene encodes a long non-coding RNA 
(lncRNA), RefSeq NR_037593, and is located about 730 bp 
upstream of the adjacent gene, QKI, which is on the opposite 
strand. A recent ENCODE survey revealed that the expression of 
almost 3% of lncRNAs shows high positive correlation with that 
of a neighboring mRNA,18 and we note that QKI is also down-
regulated in colorectal neoplasia11,19 and that this is associated 
with hypermethylation.11 Yang et al.11 and Novikov et al.20 have 
provided evidence that QKI acts as a tumor suppressor and that 
its downregulation may be significant in cancers from several dif-
ferent organs. The genomic region encompassing both CAHM 
and QKI is reported to be commonly deleted in glioblastomas.21
The gene product Qki has been shown to be an RNA-
binding protein22,23 and a deficiency of Qki protein is associated 
with developmental defects in neural and vascular tissues.24,25 
There is evidence for its tumor-suppressive actions being medi-
ated through two pathways: (1) regulation of alternate splicing, 
Figure 6. estimation of class probabilities. (A) empirical probability density plots (omitting “no-signal” results) from the 215 tested plasma samples 
(Fig. 5) with known phenotypes including colonoscopy-confirmed normal (black, 5 CAHM positives), adenoma (blue, 3 CAHM positives), early stage crc 
(red, stage 1+2, 16 CAHM positives), late stage crc (purple, stage 3+ 4, 21 CAHM positives). (B) Modeled density plots assuming a normal distribution of 
phenotypic classification including pre-malignant (green, normal + adenoma), early stage crc (red, stage 1+2) and late stage crc (purple, stage 3+4). 
(C) cumulative probability of a plasma specimen with CAHM methylation levels equal to or greater than 2.8, 148, or 22,000 pg mecAhMeqgDNA com-
ing from a patient with the indicated phenotypic classification; the mass thresholds were determined as the area under the curve (panel B) for ln(pg 
mecAhMeqgDNA) values greater than 1, 5, and 10, respectively (see dotted lines and top arrows in panel B). Likelihood ratios relative to pre-malignant 
are shown in brackets.
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www.landesbioscience.com epigenetics 1079
e.g., regulating the levels of alternate splice forms of the histone 
Macro-H2A,20 and (2) through stabilization of the microRNA 
mir20-a, which regulates genes in the TGF-β pathway.26 The 
lncRNA Gomafu/MIAT has recently been shown to bind to 
Qki and modulate its splicing specificity.27 Given the close prox-
imity of CAHM to QKI, we speculate that CAHM transcripts 
might also be RNA binding partners for the Qki protein and 
may perhaps be involved in directing its specificity. Silencing 
of CAHM, in addition to QKI, may therefore be important for 
tumor development.
In tissues from CRC patients, we have demonstrated through 
deep bisulphite sequencing that, for almost all patients, there 
was little or no methylation of CpG dinucleotides within the 
CAHM gene in DNA from histologically normal mucosa, 
whereas the locus was hypermethylated in a high proportion of 
colorectal neoplasias. This methylation is present in the body 
of the CAHM gene and extends (at least) from just after the 
presumed TSS to the center of the 3′ half of the gene. When 
our data are combined with those of Yang et al.,11 methylation 
would appear to extend across the CpG island and encompass 
both the CAHM and QKI TSS. Based on our methylation data, 
we developed a methylation-specific PCR assay (qMSP) that has 
a detection limit of approximately 5 pg meCAHMeqgDNA, an 
amount corresponding to the DNA content of a single diploid 
cell (6.6 pg). Its sensitivity is therefore similar to that of com-
mercial assays, such as that for methylated SEPT9 sequences.6 
In addition to observing frequent (56/79, 71%) hypermethyl-
ation of CAHM in DNA from CRC tissues relative to that from 
normal controls (Table 1), we report that most (17/21, 81%) 
DNA samples from colorectal adenoma tissues likewise show 
hypermethylation of CAHM.
Using the qMSP assay and an RT-qPCR assay to measure 
CAHM methylation and transcript abundance, respectively, we 
demonstrate that hypermethylation of CAHM in CRC corre-
lates with a decrease in CAHM transcription (Fig. 4A and B). 
The dose-response relationship is more switch-like than linear, 
with little or no expression (in either CRC cell lines or colorec-
tal tissue) occurring above 15% methylation (Fig. 4B and C). 
While methylation within the gene body has often been seen 
to correlate with elevated gene expression28,29, this is generally 
not associated with regions of high CpG density. In our case, 
it seems likely that high % methylation of Regions A and B 
extends across the whole CpG island including at the CAHM 
and QKI promoter regions, with hypermethylation leading to 
the epigenetic silencing of both genes. The very high GC con-
tent of this intergenic region has prevented us from assaying its 
methylation status directly.
Examination of a broader tissue set including lung, pros-
tate and breast cancers demonstrated significant specificity 
for methylation of CAHM in CRC relative to other cancers 
(Table 1). The frequent hypermethylation of CAHM in adeno-
mas suggests that this biomarker is hypermethylated relatively 
early in colorectal oncogenesis. The fact that CAHM is some-
times much more heavily methylated than SEPT9 in colorectal 
neoplasia (Table S3) suggests that CAHM methylation may be 
usefully combined with that of SEPT9 for detecting disease at 
the earliest stages.
Limitations of the study include the fact that methylation 
was measured in DNA extracted from a heterogeneous popula-
tion of cells in resected tissue. Moreover, although the initial 
deep bisulphite sequencing exercise and the subsequent valida-
tion of the qMSP assay used matched CRC/normal pairs (10 
pairs each), the colorectal tissue samples on which the bulk of 
work was conducted (21 adenoma and 89 CRC) included only 
16 paired samples (i.e., where normal and neoplastic samples 
came from the same subject, Table 1). While we have investi-
gated the correlation between CAHM methylation and disease 
stage, we have not looked for correlations with cancer subtypes 
(e.g., deficient MLH1 DNA mismatch repair and microsatel-
lite instability; CIMP status and associated BRAF mutations; 
and the presence of other classic PI3K/MAPK or Wnt pathway 
mutations).
When applied to DNA isolated from plasma, with a thresh-
old of 3 pg meCAHMeqgDNA/mL plasma (Table 1), we found 
positive CAHM methylation in 40 individuals of the 73 CRC 
patients tested (55%) and only 5 of 74 controls (7% false posi-
tives). The mean level of methylated CAHM DNA in plasma of 
CRC patients was 1893 pg meCAHMeqgDNA/mL (175–3611 
pg/mL, 95% CI). These results suggest that CRC patients carry 
a mean burden of ~300 cell equivalents of cancer-derived DNA/
mL plasma (Table S1). The high specificity of the assay (93%) 
could be a particularly attractive feature in CRC screening, as it 
would have the potential to reduce the number of unnecessary 
colonoscopy follow-up procedures.
Interestingly, the frequent hypermethylation of CAHM 
observed in colorectal adenoma tissues is not reflected in the 
plasma of adenoma patients. We hypothesize that the discrep-
ancy between adenoma tissue-plasma correlation and CRC tis-
sue-plasma correlation may be related to the higher architectural 
distortion and vascularity of cancer tissues, as well as greater 
lesion size, compared with adenomas. With a higher perfusion 
level for cancers compared with adenomas, DNA from cancers 
may more readily enter the circulation and thus be more readily 
detectable in plasma. Supporting this hypothesis, an analysis 
of the amount of methylated CAHM in DNA extracted from 
plasma relative to CRC staging showed that increasing levels of 
methylated CAHM correlated with advancing disease stage in 
these limited data (Fig. 5). Future studies could investigate the 
proportion of methylated CAHM as a function of the different 
subtypes of CRC and the clinical or phenotypic characteristics 
of the individuals in whom these cancers arise.
By fitting models of cancer classification (no CRC, early or 
late CRC), we show the potential of using the level of methyl-
ated CAHM sequences in blood to estimate the likelihood of 
a positive result being due to the presence of CRC (Fig. 6). It 
is not yet clear whether the release of pre-malignant cells (or 
their DNA) from adenomas might be more readily detected 
in fecal samples. With the potential for further assay improve-
ments, particularly in the context of using panels of biomark-
ers to improve sensitivity, CAHM hypermethylation provides a 
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biomarker worthy of future study and with promise to enhance 
the early detection and inform treatment of CRC.
Materials and Methods
Specimen collection
All tissue and blood specimens were obtained from consenting 
individuals. Ninety-six colorectal tissue specimens obtained from 
surgical resections were fresh-frozen and stored at –80 °C at a 
tertiary referral hospital tissue bank in Adelaide, South Australia. 
Access to the tissue bank for this research was approved by the 
Research and Ethics Committee of the Repatriation General 
Hospital (Adelaide) and the Ethics Committee of Flinders 
Medical Centre. Colorectal tissue specimens were classified as 
normal (n = 26), adenoma (n = 21) or adenocarcinoma (n = 87) 
on the basis of histological assessment by an expert pathologist. 
An additional panel of matched cancer/normal tissue sample 
pairs from a range of tissue types (10 pairs for each of lung, breast 
and colon; 5 pairs for prostate) was purchased from Proteogenex.
Blood plasma specimens were acquired from a commercial 
specimen bank (Proteogenex), who generated them as follows: 
Peripheral blood was drawn into K
3
EDTA VACUETTE blood 
tubes (Greiner-One, Preanalytics Cat. 456036) and transported 
to the processing laboratory on wet ice. Whole blood was centri-
fuged at 1500 g (4 °C) for 10 min within 4 h of blood draw and 
plasma was recovered. The plasma was centrifuged for a second 
time at 1500 g (4 °C) for 10 min, whereafter the supernatant 
(plasma) was collected and stored at -80 °C until further use. 
Blood specimens were classified as normal (n = 74), adenoma (n 
= 73) or CRC (n = 73) based on colonoscopy results and verified 
by histopathology in the case of adenoma or cancer. Phenotypic 
characteristics of all patients are listed in Table S1.
Tissue DNA extraction and bisulphite conversion
Fresh-frozen tissue specimens were homogenized using a 
bead homogenizer and genomic DNA extracted using a Wizard® 
Genomic DNA Purification Kit (Promega, Cat. A1120). An 
additional set of DNA extracted from 30 colorectal tissue speci-
mens (10 normal, 10 adenoma, and 10 CRC) was commercially 
sourced through Bioserve Biotechnologies. DNA from cell lines 
was also extracted using Wizard® Genomic DNA Purification 
Kit. The DNA concentration was determined by Nanodrop 
ND 1000 spectrophotometer (Nanodrop Technologies) and 1 
μg of DNA was bisulphite converted using either the EZ DNA 
Methylation-Gold Kit (Zymo Research Corp., Cat. D5005) 
or EpiTect Fast 96-well Bisulphite Conversion Kit (QIAGEN, 
Cat. 59720) as recommended by manufacturers, but with 
modified bisulphite reaction temperature conditions for the 
Zymo kit.10 The concentration of bisulphite-converted DNA 
was determined by quantitative real-time PCR using bisul-
phite conversion-specific primers for either ACTB or CFF15 as 
described in Table S2, PCR assay IDs 4 and 5, respectively. 
The bisulphite-converted tissue DNA samples were stored at 
–80 °C until further use. Enzymatically methylated human 
DNA (CpGenome Universal Methylated DNA, Millipore, Cat. 
S7821) was used as a positive methylation control, and white 
blood cell DNA (WBC DNA, Human Genomic DNA from 
human buffy coat, Roche Applied Science, Cat. 1169111201) as 
an unmethylated control.
Plasma DNA extraction and bisulphite conversion
DNA was extracted from 4 mL plasma using the “QIAamp 
Circulating Nucleic Acid Kit” (QIAGEN, Cat. 55114). The 
manufacturer’s protocol was followed except that the column 
was washed twice with ACW2 and twice with 100% ethanol, 
after which DNA was eluted by applying 35 μL of AVE buf-
fer twice over the column. This optimized protocol resulted in a 
higher DNA yield (data not shown). A total of ~33 μL DNA was 
obtained per 4 mL plasma extraction and approximately 31 μL 
was incubated at 37 °C for 1 h in a final reaction volume of 35 μL 
containing 2µg/mL tRNA (E. coli), 280 µg/mL Proteinase K and 
1% SDS. The samples were subsequently bisulphite-converted 
using the EZ DNA Methylation-Gold Kit as recommended by 
the manufacturer (Zymo) with the same modification to cycling 
conditions described above. The bisulphite-converted DNA was 
eluted using 40 μL nuclease-free water, resulting in a final vol-
ume of 36 μL. Duplicate  2μL aliquots were analyzed in the 
ACTB qPCR assay (as above) to calculate concentration of recov-
ered bisulphite-converted DNA. DNA recovered ranged from 1.1 
to 68 ng/mL plasma (mean 9.5 ng, median 5.6 ng/mL plasma). 
Triplicate 5 μL aliquots of bisulphite-converted DNA extracted 
from 4mL plasma (the equivalent of 555 μL plasma in each) were 
analyzed using the CAHM methylation-specific qPCR assay as 
described below and in Table 1.
Sequence analysis of bisulphite-treated DNAs
All nucleotide numbering in this paper is specified in hg19 
coordinates. Two regions were amplified from bisulphite-treated 
DNA: Region A spanned chr6:163 834 295–163 834 500 and 
Region B spanned chr6:163 834 621–163 834 907 (Fig. 1). 
Amplification of 10 ng bisulphite-treated tissue DNA was done 
in a total volume of 15 µL as described in Table S2, PCR assay ID 
1 (Region A) and PCR assay ID 2 (Region B). Bands of ampli-
fied DNA were ligated with linkers for sequencing on the Roche 
454 Titanium FLX system. Amplified products were mixed with 
amplicons derived from other genes from the same patient and 
the mixture ligated with bar-coded “MID” linkers (Roche, Cat. 
05619211001) so that the sample of origin for each read could be 
deduced from the sequence. Libraries of pooled amplicons were 
prepared and sequenced as described previously.10 Bisulphite 
sequencing reads were assigned to individual tissue samples using 
the bar-code sequences and a custom Python script. Alignment 
was performed using SHRiMP 1.3.230 and the in silico bisul-
phite-converted sequence expected from fully methylated DNA. 
After alignment, the SHRiMP output files were processed using 
custom R scripts and the fraction of unconverted cytosines at each 
potential CpG methylation site (identified in Fig. 1B and C) was 
determined for each sample. A WBC DNA sample (unmethyl-
ated control) as well as a 1:1 mixture with fully methylated DNA, 
were also analyzed for quality control purposes.
Measurement of CAHM methylation
Methylation-specific oligonucleotide primers (Table S2, PCR 
assay ID 3) were designed to interrogate the methylation sta-
tus of six CpG sites within the CAHM locus (Fig. 1, Region A; 
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Fig. 2A). Methylation-specific qPCR (Roche LightCycler 480 
II) was performed on 5 ng bisulphite converted tissue DNA in 
a total volume of 15 μL as described in Table S2 PCR assay ID 
3. A product with a melting temperature peak of 78.4 ± 0.9 °C 
was characteristic of the methylation-specific CAHM amplicon. 
Standard curves were constructed by assaying a 4-fold serial 
dilution of bisulphite-converted positive control CpGenome 
Universal Methylated DNA, 5000–1.2 pg) in bisulphite-con-
verted unmethylated control WBC DNA so as to give a total of 5 
ng DNA for each sample (Fig. 2B). Standard curves were run in 
triplicate on each PCR plate to allow Cycle Threshold (Ct) values 
to be converted to percent methylation (i.e., proportion of fully 
methylated DNA present). For plasma DNA assays, the input 
level of DNA, corresponding to 555 µL plasma per PCR assay, 
is variable. Therefore the standard curve was used to read off the 
amount (pg) of fully methylated genomic DNA required as input 
to obtain the Ct value actually measured in the plasma qMSP; 
the resulting value is expressed as “methylated CAHM, equiva-
lents in genomic DNA,” abbreviated as meCAHMeqgDNA.
RNA extraction and cDNA preparation
Tissue samples included 10 matched normal/CRC sample 
pairs purchased from Proteogenex and 7 matched pairs and 5 
unmatched specimens from the Adelaide cohort. Tissue and 
cell line RNA was extracted using Trizol (Invitrogen, Cat. 
10296010), and cDNA was prepared from RNA using the 
QuantiTect Reverse Transcription Kit (Qiagen, Cat. 205311). 
Since the CAHM gene lacks introns, its DNA can therefore serve 
directly as a template in the qPCR amplification (next section). 
Each cDNA synthesis was accompanied by a negative control 
reaction lacking reverse transcriptase to verify the success of the 
QuantiTect DNA removal step.
Measurement of CAHM RNA expression
Although we describe our DNA work with reference to the 
plus strand of the chromosome (e.g., sequences in Figs. 1 and 
2A), our descriptions of CAHM expression relate to the RNA (or 
cDNA second strand) and thus refer to the sequence of the chro-
mosomal minus strand. Reverse Transcriptase quantitative PCR 
(RT-qPCR) primers (Table S2, PCR assay ID 6) were designed 
to amplify a 73 bp segment from the 3′-half of the CAHM tran-
script (Fig. 1A). qPCR was performed on ~6.5 ng cDNA in a 
total volume of 10 μL as described in Table S2. Assays were 
performed in triplicate in 384-well plates; HPRT1 expression 
(Table S2, PCR assay ID 7) was used as the housekeeper ref-
erence for tissue samples, whereas ACTB (β-actin) expression 
(Table S2, PCR assay ID 8) was used for cell lines (except for 
tissue/cell line cross-comparisons, where HPRT1 was used for 
both). A product with a melting peak of 85.5 °C ± 0.6 °C was 
characteristic of the CAHM RT-qPCR amplicon; absence of 
amplification was assigned the value of Ct = 52. The amplifica-
tion efficiency was established using a 2-fold serial dilution of 
DNA from HT29 cells (9636–1204 gene copies). DNA samples 
that gave an abnormal qPCR curve or melt profile, or that were 
found to have DNA contamination (previous section), were elim-
inated prior to graphing and statistical analysis.
Statistical analysis
Statistical comparisons for expression of CAHM RNA in 
matched normal/CRC tissue samples used the paired two-tailed 
t test, as recommended by Instat v3.01 (GraphPad Software 
Inc.). For analysis of CAHM methylation in plasma, t test 
(Mann-Whitney) calculations were performed using GraphPad 
Prism v5.0d for Mac OS X (GraphPad Software). For density 
plots of amounts of meCAHMeqgDNA in plasma, samples 
with “no signal” results were omitted. The empirical density of 
ln(meCAHMeqgDNA) was estimated separately for normal, 
early stage and late stage CRC samples. Assuming a Gaussian 
distribution for the meCAHMeqgDNA values, to give the maxi-
mum entropy (the worst case) with the observed mean and vari-
ance, the densities were again estimated. Using these densities, 
we calculated the cumulative distribution function F(x) = P(X 
≤ x) and we report 1-F(x) for ln(pg meCAHMeqgDNA) values 
of 1, 5, and 10. We also report the likelihood ratio relative to the 
pre-malignant case.
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